Skip to main content

Opzelura On Trac™ Treatment Navigator Patient Education Program is for residents of the United States and Puerto Rico.

Opzelura On Trac logo
Opzelura On Trac logo

Treatment Navigator Patient 
Education Program

Together, we can help you stay on track

Repigmentation with OPZELURA takes time and commitment.
Your Treatment Navigator can help support your repigmentation journey 
with expert guidance and helpful resources.

REPIGMENTATION: SEE WHAT'S POSSIBLE

Check out Sam’s repigmentation journey. Sam, an actual OPZELURA patient, shared these photos to show her results since using OPZELURA. These photos show Sam (not a clinical trial participant) before treatment with OPZELURA and at about 2 months, 8 months, 10 months, 12 months, and 2 years of treatment.

A face of a young woman with vitiligo, showing depigmentation before treatment with OPZELURA. A face of a young woman with vitiligo, showing repigmentation progress at 2 months of treatment. A face of a young woman with vitiligo, showing repigmentation progress at 8 months of treatment. A face of a young woman with vitiligo, showing repigmentation progress at 10 months of treatment. A face of a young woman with vitiligo, showing repigmentation progress at 12 months of treatment. A face of a young woman with vitiligo, showing repigmentation progress at 2 years of treatment.

Sam used OPZELURA alone for the treatment of nonsegmental vitiligo on her face and neck. Individual results may vary. Results not typical. Clinical trial results after 6 months: 30% saw at least 75% improvement to vitiligo on the face vs 13% using placebo. To achieve a satisfactory patient response with OPZELURA, some patients may have to continue treatment for more than 6 months. If repigmentation doesn’t occur during the first 6 months, talk to your healthcare provider. Sam was compensated for her participation.

A young woman with vitiligo confidently applying treatment in the mirror. She is holding up her pointer finger applying the treatment to her cheek area.

I CLEARLY SAW THE IMPROVEMENT, WHICH MOTIVATED ME TO KEEP USING IT.

Sam, OPZELURA patient *Individual results may vary. OPZELURA is not for everyone.

Stay motivated like Sam by tapping into the support of the Treatment Navigator Patient Education Program — here to help you feel seen, supported, and never alone in your journey.

A young woman with vitiligo smiling and talking on her red cell phone up to her ear.
A young woman with vitiligo smiling and talking on her red cell phone up to her ear.

What is the Treatment Navigator Patient Education Program?

The Treatment Navigator Patient Education Program provides personalized support to help you stay on track with managing nonsegmental vitiligo using OPZELURA.

Who are the Treatment Navigators?

Treatment Navigators are trained medical professionals who offer helpful advice and support, which may help you understand and follow your treatment plan.

Treatment Navigators are provided by Incyte and do not work under the direction of your healthcare provider (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice.

GET CONNECTED

Support and resources to help you stay on track with treatment

As a participant in this program, you will receive a variety of resources designed to help you every step of the way:

An icon of two hands enclosing a heart in the middle.

Personalized Support

Get customized guidance and encouragement

An icon of a piece of paper with a plus sign in the middle.

Educational Resources

Access useful insights and helpful tips

An icon of a chat bubble with a heart in the middle.

Consistent Connection

Stay on track with regular check-ins from your Treatment Navigator. You can opt-in to receive a series of phone calls, text messages, and/or emails

These resources are designed to help you:

  • Learn more about your condition and treatment
  • Set goals and realistic expectations
  • Establish a new routine
  • Recognize signs of improvement
  • Stay motivated throughout your treatment journey
An image of a man with vitiligo facing the camera confidently crossing his arms.
An image of a man with vitiligo facing the camera confidently crossing his arms.
A combined photo of a Treatment Navigator and a young woman with Vitiligo separated by a red dotted line. On the left is the young woman with Vitiligo, wearing a pink and white top, smiling with her phone in her right hand up to her ear. On the right is the Treatment Navigator, who is a woman with short brown hair, wearing a beige top and a microphone headset smiling on the phone.
A combined photo of a Treatment Navigator and a young woman with Vitiligo separated by a red dotted line. On the left is the young woman with Vitiligo, wearing a pink and white top, smiling with her phone in her right hand up to her ear. On the right is the Treatment Navigator, who is a woman with short brown hair, wearing a beige top and a microphone headset smiling on the phone.

Join the Treatment Navigator Patient Education Program today!

The education and resources you'll receive are just a few clicks away.

ENROLL NOW

backtotop

IMPORTANT SAFETY INFORMATION AND INDICATION

Indication and Usage

OPZELURA is a prescription medicine used on the skin (topical) for the treatment of a type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older.

The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.

It is not known if OPZELURA is safe and effective in children less than 12 years of age with nonsegmental vitiligo.

Important Safety Information

OPZELURA is for use on the skin only. Do not use OPZELURA in your eyes, mouth, or vagina.

OPZELURA may cause serious side effects, including:

Serious Infections: OPZELURA contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.

OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.

Increased risk of death due to any reason (all causes): Increased risk of death has happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking a medicine in the class of medicines called JAK inhibitors by mouth.

Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers have happened in people taking a medicine in the class of medicines called JAK inhibitors by mouth. People taking JAK inhibitors by mouth have a higher risk of certain cancers including lymphoma and lung cancer, especially if they are a current or past smoker. Some people have had skin cancers while using OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA. Limit the amount of time you spend in the sunlight. Wear protective clothing when you are in the sun and use a broad-spectrum sunscreen.

Increased risk of major cardiovascular events: Increased risk of major cardiovascular events such as heart attack, stroke, or death have happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and taking a medicine in the class of medicines called JAK inhibitors by mouth, especially in current or past smokers.

Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening. Blood clots in the vein of the legs (deep vein thrombosis, DVT) and lungs (pulmonary embolism, PE) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a medicine in the class of medicines called JAK inhibitors by mouth.

Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia). If needed, your healthcare provider will do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen.

Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides.

Before starting OPZELURA, tell your healthcare provider if you:

  • have an infection, are being treated for one, or have had an infection that does not go away or keeps coming back
  • have diabetes, chronic lung disease, HIV, or a weak immune system
  • have TB or have been in close contact with someone with TB
  • have had shingles (herpes zoster)
  • have or have had hepatitis B or C
  • live, have lived in, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use OPZELURA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common.
  • think you have an infection or have symptoms of an infection such as: fever, sweating, or chills, muscle aches, cough or shortness of breath, blood in your phlegm, weight loss, warm, red, or painful skin or sores on your body, diarrhea or stomach pain, burning when you urinate or urinating more often than usual, feeling very tired.
  • have ever had any type of cancer, or are a current or past smoker
  • have had a heart attack, other heart problems, or a stroke
  • have had blood clots in the veins of your legs or lungs in the past
  • have high cholesterol or triglycerides
  • have or have had low white or red blood cell counts
  • are pregnant or plan to become pregnant. It is not known if OPZELURA will harm your unborn baby. There is a pregnancy exposure registry for individuals who use OPZELURA during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become exposed to OPZELURA during pregnancy, you and your healthcare provider should report exposure to Incyte Corporation at 1-855-463-3463 or www.opzelura.pregnancy.incyte.com.
  • are breastfeeding or plan to breastfeed. It is not known if OPZELURA passes into your breast milk. Do not breastfeed during treatment with OPZELURA and for about 4 weeks after the last dose.

After starting OPZELURA:

  • Call your healthcare provider right away if you have any symptoms of an infection. OPZELURA can make you more likely to get infections or make worse any infections that you have.
  • Get emergency help right away if you have any symptoms of a heart attack or stroke while using OPZELURA, including:
    • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
    • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
    • pain or discomfort in your arms, back, neck, jaw, or stomach
    • shortness of breath with or without chest discomfort
    • breaking out in a cold sweat
    • nausea or vomiting
    • feeling lightheaded
    • weakness in one part or on one side of your body
    • slurred speech
  • Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with OPZELURA, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, or shortness of breath or difficulty breathing.
  • Tell your healthcare provider right away if you develop or have worsening of any symptoms of low blood cell counts, such as: unusual bleeding, bruising, tiredness, shortness of breath, or fever.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of OPZELURA in people treated for nonsegmental vitiligo include: acne at the application site, itching at the application site, common cold (nasopharyngitis), headache, urinary tract infection, redness at the application site, and fever.

These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.

Please see Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.

Indication and Usage

OPZELURA is a prescription medicine used on the skin (topical) for the treatment of a type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older.

Important Safety Information

OPZELURA may cause serious side effects, including:

Serious Infections: OPZELURA contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections.